Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Dose-Tapering Regimen for Weight-Loss Maintenance
NCT07783854Phase 4Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2027
01
Overview
Phase 4, randomised, open-label trial of semaglutide in obesity and Overweight (2 arms). Primary endpoint: Percentage change in body weight at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07783854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783854.